

Case Study

Phase 1 Dose Escalation Study With A Bispecific Antibody In Relapse Refractory Multiple Myeloma (RRMM)

Cerba Research Performing 220+ Routine & Specialty Tests

Scope

Patients Screened: 248

Patients Enrolled: 183

Sites: 11

Countries: 2

Regions: US, EU

Study duration: 43 months

Cerba Research involved in 220+ routine & specialty tests such as FCM, FISH, CD138+ cell isolation & count


Key Achievements

↑ +25,000 samples managed to date

↑ Strong FCM expertise

↑ Continued partnership with the large CRO & Sponsor on liquid tumor trials

Timeline



Challenges

Cerba Research involved in 220+ tests

Such as CD138+ cell isolation & count, BCMA, TBNK lymphocyte FCM, T-cell subsets FCM and more

Solutions

↑ Flexibility in working with referral labs & subcontractor labs

↑ FCM in-house design & validation

Cerba Research Data In-house (MSN F55); RRMM=Relapsed or Refractory Multiple Myeloma; FCM=Flow CytoMetry; FISH=Fluorescence In-Situ Hybridization; FPFV=First-Patient First-Visit; LPLV=Last-Patient Last-Visit; DBL=DataBase Lock